ESMO: Novel Checkpoint Inhibitors From Merck And BMS Show Promise

Patients Progressing On PD-1/PD-L1s Need Options

 
• By Andrew McConaghie
  
ESMO publications
This year's virtual ESMO saw noteworthy advances in esophageal and melanoma combination therapies, with a crop of new mechanisms also showcased.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip